SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (1155)7/25/2003 9:35:17 AM
From: Icebrg  Read Replies (2) | Respond to of 1834
 
Acquisitions

During the call yesterday Lynch touched upon their current thinking with regard to product acquisitions. They are looking for

- approved products. They would like to have more products for the sales force the sales force Pfizer is setting up for them. They are either/or looking for an orphaned product from one of the major pharmas or possibly to buy a European company.

- late stage product candidates. As their development group is about to finish their Indiplon assignment, they will need something to do. Lynch said that they are looking for 1-3 phase III product candidates, which they would like to get their hands on for further development.

It seems that getting hold of some development candidates is closer in time.

Erik



To: Icebrg who wrote (1155)11/4/2003 4:31:00 PM
From: Icebrg  Read Replies (1) | Respond to of 1834
 
Quarterly and 12m running figures.



Quarterly Q3_03 Q2_03 Q1_03 Q4_02 Q3_02 Q2_02 Q1_02

Revenue 11,7 11,3 6,7 3,2 4,4 3,8 4,5
Sponsored R & D 17,6 33,6 31,0 0,7 0,6 0,5 0,4
Total revenue 29,3 44,9 37,7 3,9 5,0 4,3 4,9

Cost of Revenue
Gross Profit 29,3 44,9 37,7 3,9 5,0 4,3 4,9

S,G & A -5,3 -5,1 -4,7 -3,6 -3,3 -3,2 -2,7
R&D -37,5 -52,3 -48,3 -41,6 -24,2 -23,1 -20,0
Total Op. Exp. -42,8 -57,4 -53,0 -45,2 -27,5 -26,3 -22,7

Operating Inc. -13,6 -12,5 -15,3 -41,3 -22,5 -22,0 -17,8

Interest, net 3,7 2,2 2,1 2,4 2,3 2,2 1,9
Other, net 0,1
Total Non-op. 3,7 2,3 2,1 2,4 2,3 2,2 1,9

NI bef. Taxes -9,8 -10,2 -13,2 -38,9 -20,2 -19,8 -15,9

Prov. Taxes -0,2
NI after taxes -9,8 -10,2 -13,4 -38,9 -20,2 -19,8 -15,9


12m running Oct-Sept Jul-Jun Apr-Mar 2002 2001 2000 1999 1998

Revenue 32,9 25,6 18,1 15,9 39,8 13,2 15,7 14,9
Sponsored R & D 82,9 65,9 32,8 2,2 1,4 1,4 1,1 1,2
Total revenue 115,8 91,5 50,9 18,1 41,2 14,6 16,8 16,1

Gross Profit 115,8 91,5 50,9 18,1 41,2 14,6 16,8 16,1

S,G & A -18,7 -16,7 -14,8 -12,7 -10,9 -10,0 -7,5 -6,6
R&D -179,7 -166,4 -137,2 -108,9 -74,3 -40,2 -29,2 -21,8
Other op. Exp. -4,9
Total Op. Exp. -198,4 -183,1 -152,0 -121,6 -85,2 -50,2 -36,7 -33,3

Operating Inc. -82,7 -91,6 -101,1 -103,5 -44,0 -35,6 -19,9 -17,2

Interest, net 10,4 9,0 9,0 8,9 6,7 6,0 2,0 -3,2

Other, net 0,1 0,1 0,0 0,2 0,4 1,0 1,1 0,5
Total Non-op. 10,5 9,1 9,0 9,1 7,1 7,0 3,1 -2,7

NI bef. Taxes -72,1 -82,5 -92,1 -94,4 -36,9 -28,6 -16,8 -19,9

Prov. Taxes -0,2 -0,2 -0,2 -0,1 -0,3
NI after taxes -72,3 -82,7 -92,3 -94,4 -37,0 -28,9 -16,8 -19,9